RAPP 8-K 2026-11-04
Rapport Therapeutics, Inc. (RAPP) 8-K dated 2026-11-04 — accession 0001193125-26-446202.
Rapport Therapeutics, Inc. (RAPP) is a biotechnology company listed on US.
RAPP: Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides…
This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.
Latest reported RAPP revenue for 2026-06-30 was $0. Net income was -$56.6M. Revenue was down 100.0% from 2026-03-31 to 2026-06-30. RAPP currently screens at market cap $532.9M.
Not investment advice. The RAPP SEC hub lists recent forms. The stock page is the research view.
- Guidance
- expects that cash, cash equivalents, and short-term investments as of September 30, 2026, together with net proceeds from the O
Why it matters
- expects that cash, cash equivalents, and short-term investments as of September 30, 2026, together with net proceeds from the O